Please assess the completion status of the following clinical trial:

Trial Title: Comparative Efficacy of an Intensified Re-vaccination Scheme for Hepatitis B Virus Infection Among Patients Infected With HIV .

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Older than 18 years of age.~* Patients infected with Human Immunodeficiency Virus (HIV)~* Failed previous vaccination with a standard dose scheme of recombinant hepatitis B vaccine (20mcg at 0, 1 and 6 months). Nonresponders will be considered as those patients presenting a hepatitis B surface antigen antibody titer lower than 10UI/mL 4 to 8 weeks after the last dose of the vaccine.~* Provision of informed consent.~Exclusion Criteria:~* Proven Hepatitis B virus infection (acute or chronic).~* Proven hypersensitivity to the vaccine or any of its components.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Recombinant Hepatitis B Virus Vaccine (High Dose) (Type: EXPERIMENTAL): Patients allocated to this arm will receive three doses of 40mcg each of recombinant hepatitis B vaccine (Engerix-B (R)). Doses will be administered at 0, 1 and 2 months.
- Recombinant Hepatitis B Virus Vaccine (Standard Dose) (Type: ACTIVE_COMPARATOR): Patients allocated to this arm will receive three doses of 20mcg each of recombinant hepatitis B vaccine (Engerix-B (R)). Doses will be administered at 0, 1 and 2 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).